Alkylating Agents in Bronchogenic Carcinoma

Green, R A; Humphrey, Edward W.; Close, H.G.; Patno, Mary Ellen

doi:10.1097/00043764-197006000-00014

Cited by 41 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brunner, Marthaler and Muller (1973) found that cyclophosphamide i.v. in intermittent courses over a period of 2 years led to a significantly tncreased recurrence rate and mortality compared with an untreated control group, but Green et al (1969), in a controlled study, reported improved survival of patients when the drug was administered i.v. in several courses.…”

Section: Discussionmentioning

confidence: 97%

“…in several courses. These studies were of all cell types but there is some evidence that cyclophosphamide is more active against small-cell tumours (Green et al, 1969;Higgins, 1972;H0st, 1973). This was not the experience in the present study, nor in Tattersall and Ryall's investigation (1975) in patients treated with radiotherapy plus intermittent combination chemotherapy, including cyclophosphamide.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

Stott¹,

Stephens²,

Fox³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

Summary.-This report gives the 5-year findings of a double-blind study of longterm cytotoxic chemotherapy as an adjuvant to surgery in patients receiving busulphan or cyclophosphamide for carcinoma of the bronchus compared with a group receiving a placebo. Of 243 patients initially allocated busulphan, 234 cyclophosphamide and 249 placebo, 28%, 27% and 34%0 respectively were alive at 5 years. There were significant associations between mortality from bronchial carcinoma and histological involvement of the resected intrathoracic nodes and the histology of the tumour.Haematological toxicity, especially thrombocytopenia, was frequent and severe in the busulphan series, and low platelet counts continued long after chemotherapy was stopped.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

Stott¹,

Stephens²,

Fox³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…With increasingly sophisticated methods for tumour detection it is now becoming recognised that the vast majority of patients, whether or not conventionally presenting with limited stage disease, usually have systemic disease. This is substantiated by the eventual patterns of progression as well as by the long observed phenomenon that the only treatment with any survival impact in this disease has been systemic therapy (Green et al, 1969;Smyth et al, 1986)). Although additional loco-regional therapy therefore needs to be considered to improve control of primary tumour, there is a real possibility in the autologous marrow rescue programmes that infusing explanted marrow allowed the introduction of viable clonogenic tumour stem cells Hay et al, 1988).…”

mentioning

confidence: 89%

Small cell lung cancer

Leonard

1989

Br J Cancer

View full text Add to dashboard Cite

“…Patients with disseminated untreated disease have a mean survival time of 7 weeks (Green et al, 1969). Spread is so rapid via lymph and haematogeneous routes that -65% of cases (Alberto et al, 1976) present with disseminated disease.…”

mentioning

confidence: 99%

“…SCLC has a rapid doubling time of 30-45 days (Green et al, 1969;Salazar et al, 1976) which makes it responsive to chemotherapy and radiotherapy. Good responses have been obtained using either or both of these treatments.…”

mentioning

confidence: 99%

Small-cell lung cancer: initial treatment with sequential hemi-body irradiation VS 3-drug systemic chemotherapy

Urtasun¹,

Belch²,

McKinnon³

et al. 1982

Br J Cancer

View full text Add to dashboard Cite

The therapeutic value of sequential hemi-body irradiation (HBI) as a primary treatment for small-cell lung cancer (SCLC) was compared to 3-drug cyclic chemotherapy (CC) in a group of 64 patients with early and advanced disease. Thirty patients were randomized to receive sequential HBI and 34 to receive CC. All patients received a local radiation boost to the primary lesion. An overall response rate of 87% was obtained in patients treated with sequential HBI and 88% in patients treated with CC. In patients with early disease, the estimated median survival was 43 weeks when treated with HBI and 42 weeks when treated with CC, but in advanced disease the estimated median survival was 15 weeks and 44 weeks respectively. Of the patients with an initial complete response, the estimated median survival was 51 weeks for HBI and 62 weeks for CC. From these observations we suggest that sequential HBI treatment technique with local radiation boost is an efficient method of tumour control in patients with early small-cell lung cancer.

show abstract

Alkylating Agents in Bronchogenic Carcinoma

Cited by 41 publications

References 0 publications

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

Small cell lung cancer

Small-cell lung cancer: initial treatment with sequential hemi-body irradiation VS 3-drug systemic chemotherapy

Contact Info

Product

Resources

About